KA2507 has completed a Phase I clinical trial at The University of Texas MD Anderson Cancer Center, investigating its safety and efficacy in patients with solid tumours. KA2507 showed excellent tolerability with good target engagement and selectivity. Data were presented at the American Association for Cancer Research (AACR) annual meeting on 27 April 2020. KA2507 has significant potential in the treatment of cancer, as a single agent or in combination therapy.
For more information, please visit ClinicalTrials.gov: NCT03008018.
We had plans in place for a Phase II clinical study in patients with cholangiocarcinoma, ABC-11, within a network of UK hospitals led by the UCL-CRUK Clinical Trials Centre. However, these were disrupted by the unprecedented impact of the COVID-19 pandemic on the UK health service, leading to cancellation of the trial.
Histone deacetylase 6 (HDAC6) is structurally-, expressionally-, and functionally-distinctive within the HDAC superfamily, and represents an important drug target for cancer therapy. Despite its name, it is principally a non-histone protein deacetylase, regulating the acetylation status of several substrates implicated in cancer, including α-tubulin and HSP90.
Its attractiveness as a cancer drug target stems from its overexpression in several solid tumour types, its regulation of cell motility, and its role in apoptosis, stress response and aggresomal protein degradation. HDAC6 has also been implicated in cell signal transduction and in oncogenic processes such as dysregulation of ciliation. More recently, a role for HDAC6 in the control of anti-tumour immunity has emerged.